In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on ClearPoint Neuro (CLPT – Research Report). The company’s shares closed last Friday at $5.87.
According to TipRanks, Takkinen is a 2-star analyst with an average return of 0.9% and a 40.98% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as ClearPoint Neuro, Silk Road Medical, and Inotiv.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ClearPoint Neuro with a $9.50 average price target.
The company has a one-year high of $9.87 and a one-year low of $4.05. Currently, ClearPoint Neuro has an average volume of 157.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ClearPoint Neuro (CLPT) Company Description:
Clearpoint Neuro, Inc. engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart. It conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform is comprises of ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Irvine, CA.
Read More on CLPT:
- ClearPoint Neuro announces FDA clearance of Prism Bone Anchor Accessory
- ClearPoint Neuro initiates limited market release of SmartFrame OR
- ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
- ClearPoint congratulates partner PTC Therapeutics on completion of its BLA
- ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
